Global Incidence & Mortality
Liver cancer remains a major global health challenge with significant regional variations in incidence and survival rates.
Global Liver Cancer Burden
Liver cancer is the 6th most commonly diagnosed cancer and the 3rd leading cause of cancer death worldwide.
According to GLOBOCAN 2024 estimates, there were approximately 866,000 new cases of liver cancer and 758,000 deaths globally. The disease disproportionately affects developing countries, with over 80% of cases occurring in Asia and Africa.
Hepatocellular carcinoma (HCC) accounts for 75-85% of primary liver cancer cases, followed by intrahepatic cholangiocarcinoma (10-15%). The incidence has been rising in traditionally low-risk regions due to increasing rates of metabolic syndrome and NAFLD.
Survival rates remain poor, with a global 5-year survival rate of approximately 8.2%. Early detection through surveillance in high-risk populations can improve outcomes significantly.
📊 Key Global Statistics (2024)
Incidence Rate (ASR): 9.3 per 100,000
Mortality Rate (ASR): 8.1 per 100,000
Male:Female Ratio: 2.8:1
Median Age at Diagnosis: 66 years
2024 Global Statistics
Comprehensive breakdown of liver cancer incidence and mortality worldwide
Global Incidence
New cases diagnosed in 2024, representing 4.7% of all cancer cases.
- 6th most common cancer worldwide
- 606,000 cases in males
- 260,000 cases in females
- Increasing trend in Western countries
Global Mortality
Deaths attributed to liver cancer in 2024, 8.3% of all cancer deaths.
- 3rd leading cause of cancer death
- 523,000 male deaths
- 235,000 female deaths
- 87% mortality-to-incidence ratio
Survival Rates
Global 5-year relative survival rate for liver cancer patients.
- 35% for localized disease
- 12% for regional spread
- 3% for distant metastasis
- Improving with early detection
Regional Incidence Variations
Age-standardized incidence rates (ASR) per 100,000 population by region
Highest incidence worldwide, driven by chronic hepatitis B prevalence.
High burden due to viral hepatitis and aflatoxin exposure.
Egypt has world's highest HCC incidence due to historical schistosomiasis and HCV.
Increasing incidence due to metabolic syndrome and alcohol consumption.
Rising incidence attributed to obesity epidemic and past HCV infections.
Top 20 Countries by Incidence (2024)
Age-standardized rates (ASR) per 100,000 and absolute numbers
| Rank | Country | New Cases | ASR | Deaths | M/I Ratio |
|---|---|---|---|---|---|
| 1 | Mongolia | 2,950 | 86.2 | 2,800 | 95% |
| 2 | Egypt | 35,000 | 32.1 | 33,000 | 94% |
| 3 | Gambia | 850 | 28.5 | 810 | 95% |
| 4 | Vietnam | 26,500 | 25.3 | 24,500 | 92% |
| 5 | Laos | 1,800 | 24.1 | 1,700 | 94% |
| 6 | China | 367,000 | 23.7 | 326,000 | 89% |
| 7 | Thailand | 28,000 | 22.8 | 25,500 | 91% |
| 8 | Cambodia | 3,200 | 21.5 | 3,000 | 94% |
| 9 | South Korea | 15,500 | 20.1 | 11,800 | 76% |
| 10 | Myanmar | 11,000 | 19.8 | 10,200 | 93% |
| 11 | Taiwan | 11,500 | 19.2 | 8,900 | 77% |
| 12 | Japan | 45,000 | 18.5 | 32,000 | 71% |
| 13 | Moldova | 850 | 17.9 | 780 | 92% |
| 14 | Guinea | 2,100 | 17.2 | 2,000 | 95% |
| 15 | North Korea | 4,800 | 16.8 | 4,500 | 94% |
| 16 | Hong Kong | 1,850 | 16.5 | 1,450 | 78% |
| 17 | Sudan | 6,500 | 15.9 | 6,200 | 95% |
| 18 | Italy | 12,500 | 15.2 | 10,800 | 86% |
| 19 | Spain | 8,500 | 14.8 | 7,200 | 85% |
| 20 | France | 10,500 | 14.1 | 8,900 | 85% |
🌍 Regional Risk Factors Summary
Asia/Africa: Chronic HBV (55% of global cases), HCV, aflatoxin exposure
Western Countries: Alcohol-related cirrhosis (30%), NAFLD/NASH (25%), HCV (20%)
Prevention Impact: HBV vaccination reduced childhood HCC by 70% in Taiwan
Incidence Trends & Projections
Historical trends and future projections for liver cancer burden
Historical Trends
Global incidence increased by 135% since 1990, driven by population growth and risk factor changes.
- HBV-related HCC decreasing in Asia
- HCV-related HCC peaked 2015-2020
- NAFLD-related HCC rising rapidly
- 2.5% annual increase in USA
Future Projections
Expected changes in global liver cancer burden based on current trends.
- 55% increase in global cases by 2040
- 1.3 million new cases annually by 2040
- 25% reduction possible with prevention
- HBV vaccination impact continues
Scientific References
Data sourced from authoritative global cancer registries and peer-reviewed publications.
- Sung H, et al. (2024). Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide. CA: A Cancer Journal for Clinicians.
- World Health Organization. (2024). World Cancer Report: Cancer Research for Cancer Prevention.
- Rumgay H, et al. (2024). Global burden of primary liver cancer in 2024 and predictions to 2040. Journal of Hepatology.
- National Cancer Institute. (2025). SEER Cancer Statistics Review: Liver and Intrahepatic Bile Duct Cancer.
- Global Burden of Disease Liver Cancer Collaboration. (2024). The global, regional, and national burden of liver cancer, 1990–2021. The Lancet Gastroenterology & Hepatology.
Concerned About Liver Cancer Risk?
Get personalized risk assessment, screening recommendations, or second opinion from global liver cancer specialists.